Background: Proton pump inhibitors (PPIs) can trigger immediate-type hypersensitivity reactions (HSRs). Three main patterns of cross-reactivity have been identified: reactions to a single PPI, selective cross-reactions, and cross-reactions with all PPIs. Several hypotheses have been advanced, but no consensus has been reached. Objective: We sought to identify immediate-type hypersensitivity cross-reactions to PPIs using real-world data about hypersensitivity testing from French pharmacovigilance cases. Methods: Potentially relevant immediate-type HSRs reported from January 1985 to February 2015 were extracted from the French pharmacovigilance database using a standardized MedDRA query (SMQ). Cases describing skin tests or oral provocation tests (OPTs) performed with several PPIs that yielded at least one positive result were included. Results: The SMQ extracted 2,119 cases, 38 of which were included in our study. Data collected from skin tests and OPTs indicated cross-reactions with all PPIs (n = 1), reactions to a single PPI (n = 14), or selective cross-reactions (n = 23). Esomeprazole, omeprazole, and pantoprazole concerned 78% of all selective cross-reactions. In more than half of the cases (55.3%), only 2 PPIs were tested. Conclusion: To the best of our knowledge, this PPI cross-reactivity study is the largest to date in terms of population size, describing 38 immediate-type HSRs to PPIs explored by skin tests or OPTs. This paucity of data belies the lack of standardized procedures for PPI hypersensitivity testing. It is likely that PPI HSR workups in everyday clinical practice are often incomplete. Further research to gain insight into selective cross-reactions between PPIs is needed. In the meantime, thorough workups should be completed when a PPI is suspected to have triggered an HSR, instead of routine contraindication to all PPIs.

1.
Savarino
V
,
Di Mario
F
,
Scarpignato
C
.
Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety
.
Pharmacol Res
.
2009
Mar
;
59
(
3
):
135
53
.
[PubMed]
1043-6618
2.
Summary of Product Characteristics - MOPRAL 20 mg, delayed-release capsule
[Internet]. Base de données publique des médicaments.
2017
[cited 2017 Sep 4]. Available from: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=64103828&typedoc=R#RcpPremiereAutorisation
3.
Summary of Product Characteristics - INEXIUM 20 mg, delayed-release tablet
[Internet]. Base de données publique des médicaments.
2017
[cited 2016 Mar 21]. Available from: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=64578892&typedoc=R
4.
Summary of Product Characteristics - EUPANTOL 20 mg, delayed-release tablet
[Internet]. Base de données publique des médicaments.
2017
[cited 2016 Mar 21]. Available from: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=67232155&typedoc=R
5.
Summary of Product Characteristics - PARIET 10 mg, delayed-release tablet
[Internet]. Base de données publique des médicaments.
2017
[cited 2016 Mar 21]. Available from: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66035518&typedoc=R
6.
Summary of Product Characteristics - LANZOR 15 mg, delayed-release capsule
[Internet]. Base de données publique des médicaments.
2017
[cited 2016 Mar 21]. Available from: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66475001&typedoc=R
7.
Lobera
T
,
Navarro
B
,
Del Pozo
MD
,
González
I
,
Blasco
A
,
Escudero
R
, et al.
Nine cases of omeprazole allergy: cross-reactivity between proton pump inhibitors
.
J Investig Allergol Clin Immunol
.
2009
;
19
(
1
):
57
60
.
[PubMed]
1018-9068
8.
Porcel
S
,
Rodríguez
A
,
Jiménez
S
,
Alvarado
M
,
Hernández
J
.
Allergy to lansoprazole: study of cross-reactivity among proton-pump inhibitors
.
Allergy
.
2005
Aug
;
60
(
8
):
1087
8
.
[PubMed]
0105-4538
9.
Caboni
S
,
Gunera-Saad
N
,
Ktiouet-Abassi
S
,
Berard
F
,
Nicolas
JF
.
Esomeprazole-induced DRESS syndrome. Studies of cross-reactivity among proton-pump inhibitor drugs
.
Allergy
.
2007
Nov
;
62
(
11
):
1342
3
.
[PubMed]
0105-4538
10.
Bong
JL
,
Lucke
TW
,
Douglas
WS
.
Lichenoid drug eruption with proton pump inhibitors
.
BMJ
.
2000
Jan
;
320
(
7230
):
283
.
[PubMed]
0959-8138
11.
Sánchez-Morillas
L
,
Rojas Pérez-Ezquerra
P
,
González Mendiola
R
,
Gómez-Tembleque Ubeda
P
,
Santos Alvarez
A
,
Laguna-Martínez
JJ
.
Eleven cases of omeprazole hypersensitivity: diagnosis and study of cross-reactivity
.
J Investig Allergol Clin Immunol
.
2014
;
24
(
2
):
130
2
.
[PubMed]
1018-9068
12.
Garrido Fernández
S
,
Cumplido
JA
,
Rábano
A
,
Martínez
D
,
Blanco
C
,
Carrillo
T
.
Allergy to proton pump inhibitors: diagnosis and assessment of cross-reactivity
.
J Investig Allergol Clin Immunol
.
2008
;
18
(
2
):
140
1
.
[PubMed]
1018-9068
13.
Sobrevia Elfau
MT
,
Garcés Sotillos
M
,
Ferrer Clavería
L
,
Segura Arazuri
N
,
Monzón Ballarin
S
,
Colás Sanz
C
.
Study of cross-reactivity between proton pump inhibitors
.
J Investig Allergol Clin Immunol
.
2010
;
20
(
2
):
157
61
.
[PubMed]
1018-9068
14.
Abdul Razzak
E
,
Tomás
M
,
Tornero
P
,
Herrero
T
.
Nine cases of allergy to omeprazole
.
J Investig Allergol Clin Immunol
.
2012
;
22
(
3
):
228
30
.
[PubMed]
1018-9068
15.
Vovolis
V
,
Koutsostathis
N
,
Stefanaki
E
.
IgE-mediated anaphylaxis to proton pump inhibitors - cross-reacting study
.
Allergy
.
2008
Sep
;
63
(
9
):
1251
2
.
[PubMed]
0105-4538
16.
Silva
D
,
Castro
E
,
Cernadas
J
.
Allergy suspicion to proton pump inhibitors - taking advantage of cross-reactivity
.
J Allergy Clin Immunol
.
2013
Feb
;
131
(
2
):
AB165
. 0091-6749
17.
Bergmann
M
,
Guignard
B
,
Ribi
C
.
[Hypersensitivity to proton pump inhibitors]
.
Rev Med Suisse
.
2012
Apr
;
8
(
337
):
830
5
.
[PubMed]
1660-9379
18.
Bose
S
,
Guyer
A
,
Long
A
,
Banerji
A
.
Evaluation and management of hypersensitivity to proton pump inhibitors
.
Ann Allergy Asthma Immunol
.
2013
Dec
;
111
(
6
):
452
7
.
[PubMed]
1081-1206
19.
Bonadonna
P
,
Lombardo
C
,
Bortolami
O
,
Bircher
A
,
Scherer
K
,
Barbaud
A
, et al.
Hypersensitivity to proton pump inhibitors: diagnostic accuracy of skin tests compared to oral provocation test
.
J Allergy Clin Immunol
.
2012
Aug
;
130
(
2
):
547
9
.
[PubMed]
0091-6749
20.
Kepil Özdemir
S
,
Yılmaz
I
,
Aydin
Ö
,
Büyüköztürk
S
,
Gelincik
A
,
Demirtürk
M
, et al.
Immediate-type hypersensitivity reactions to proton pump inhibitors: usefulness of skin tests in the diagnosis and assessment of cross-reactivity
.
Allergy
.
2013
Aug
;
68
(
8
):
1008
14
.
[PubMed]
0105-4538
21.
Kepil Özdemir
S
,
Öner Erkekol
F
,
Ünal
D
,
Büyüköztürk
S
,
Gelincik
A
,
Dursun
AB
, et al.
Management of Hypersensitivity Reactions to Proton Pump Inhibitors: A Retrospective Experience
.
Int Arch Allergy Immunol
.
2016
;
171
(
1
):
54
60
.
[PubMed]
1018-2438
22.
European Medicines Agency
. Overview - Pharmacovigilance [Internet]. www.ema.europa.eu. [cited 2017 Nov 5]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000258.jsp
23.
Mertes
PM
,
Alla
F
,
Tréchot
P
,
Auroy
Y
,
Jougla
E
;
Groupe d’Etudes des Réactions Anaphylactoïdes Peranesthésiques
.
Anaphylaxis during anesthesia in France: an 8-year national survey
.
J Allergy Clin Immunol
.
2011
Aug
;
128
(
2
):
366
73
.
[PubMed]
0091-6749
24.
Technical Agency for Information on Hospital Care
. Technical Agency for Information on Hospital Care [Internet].
2016
[cited 2017 Nov 5]. Available from: http://www.atih.sante.fr/sites/default/files/public/content/2232/atih_presentation_0.pdf
25.
Asfari
H
,
Bousquet
C
,
Paviot
BT
,
Bellet
F
,
Mounier
G
,
Marsille
F
, et al.
Chocs anaphylactiques d’origine médicamenteuse : sous-notification et PMSI
.
Therapie
.
2014
Dec
;
69
(
6
):
483
90
. 0040-5957
26.
Afssaps. [Pharmacovigilance Good Practices].
2011
.
27.
International Conference on Harmonisation. [Introductory Guide MedDRA] Version 20.0.
2017
.
28.
International Conference on Harmonisation. [Introductory Guide for Standardised MedDRA Queries (SMQs)] Version 17.1.
2014
.
29.
Brockow
K
,
Romano
A
,
Blanca
M
,
Ring
J
,
Pichler
W
,
Demoly
P
.
General considerations for skin test procedures in the diagnosis of drug hypersensitivity
.
Allergy
.
2002
Jan
;
57
(
1
):
45
51
.
[PubMed]
0105-4538
30.
Demoly
P
,
Piette
V
,
Messaad
D
.
[Diagnosis of drug allergy]
.
Rev Mal Respir
.
2002
Apr
;
19
(
2 Pt1
):
260
2
.
[PubMed]
0761-8425
31.
Aberer
W
,
Bircher
A
,
Romano
A
,
Blanca
M
,
Campi
P
,
Fernandez
J
, et al.;
European Network for Drug Allergy (ENDA)
;
EAACI interest group on drug hypersensitivity
.
Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations
.
Allergy
.
2003
Sep
;
58
(
9
):
854
63
.
[PubMed]
0105-4538
32.
Mayorga
C
,
Celik
C
,
Rouzaire
P
,
Whitaker
P
,
Bonadonna
P
,
Rodrigues Cernadas
J
, et al.
In vitro diagnostic tests for immediate and delayed DHR - EAACI [Internet].
2017
[cited 2016 Mar 17]. Available from: http://www.eaaci.org/activities/task-forces/ongoing-task-forces/716-drug-hypersensitivity/2241-in-vitro-task-force-executive-summary.html
33.
Barbaud
A
.
Usefulness of drug patch testing in cutaneous allergy: what is new?
Rev Fr Allergol Immunol Clin
.
2003
Jun
;
43
(
4
):
222
6
. 0335-7457
34.
Arimone
Y
,
Bidault
I
,
Dutertre
JP
,
Gérardin
M
,
Guy
C
,
Haramburu
F
, et al.;
Cercle de Réflexion sur l’Imputabilité (CRI)
.
Updating the French method for the causality assessment of adverse drug reactions
.
Therapie
.
2013
Mar-Apr
;
68
(
2
):
69
76
.
[PubMed]
0040-5957
35.
ANSM
. [Analysis of medicines sales in France in 2013].
2014
.
36.
Haute Autorité de Santé
. [Proton pump inhibitors use in adults: reassessment].
2009
.
37.
Esteves
M
,
Rollason
V
,
Grosgurin
O
.
[Proton pump inhibitors overprescription]
.
Rev Med Suisse
.
2017
Oct
;
13
(
579
):
1782
6
.
[PubMed]
1660-9379
38.
The first over-the-counter PPI will be available in pharmacies on Friday
[Internet]. Le Quotidien du Pharmacien.
2009
[cited 2017 Sep 4]. Available from: http://www.lequotidiendupharmacien.fr/actualite/breve/2009/12/02/le-premier-ipp-sans-ordonnance-arrive-vendredi-en-pharmacie_144416
39.
Prescrire Rédaction
.
[Esomeprazole : the third over-the-counter PPI]
.
Rev Prescrire.
2014
Oct
;
34
(
372
):
743
.
40.
France. Decree No. 2012-1244 of 8 November 2012 relating to strengthening of safety provisions regarding medicinal products for human use subject to marketing authorization and to pharmacovigilance. JORF n°0261 du 9 novembre
2012
page 17558 texte n° 8.
41.
Thiessard
F
,
Roux
E
,
Miremont-Salamé
G
,
Fourrier-Réglat
A
,
Haramburu
F
,
Tubert-Bitter
P
, et al.
Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001)
.
Drug Saf
.
2005
;
28
(
8
):
731
40
.
[PubMed]
0114-5916
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.